The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
复制标题
DOI：
10.3346/jkms.2012.27.11.1364
复制
发表时间：
2012-11
影响因子：
4.5
通讯作者：
Mizuno K
中科院分区：
文献类型：
--
作者：
Kubota Y;Miyamoto M;Takagi G;Ikeda T;Kirinoki-Ichikawa S;Tanaka K;Mizuno K
糖尿病患者动脉粥样硬化早期即存在血管内皮功能受损。本研究的目的是确定西格列汀改善2型糖尿病患者血管内皮功能的机制。本研究是一项开放标签、前瞻性、观察性、单组试验。40例患者接受50 mg西格列汀每日一次治疗，持续12周。分别于治疗前和治疗后12周测定血浆脂联素和血流介导的血管舒张功能（FMD）。治疗后%FMD显著增加（4.13 ± 1.59 vs 5.12 ± 1.55，P < 0.001），而硝酸甘油介导的血管扩张（NMD）无明显变化。血浆脂联素水平显著升高（13.0 ± 11.3vs14.3 ± 12.8，P < 0.001）。FMD的变化与血浆脂联素的变化呈显著正相关（r = 0.322，P < 0.05）。多元线性回归分析显示，FMD的改善与血浆脂联素水平有关（P < 0.05）。西格列汀治疗2型糖尿病患者可逆转血管内皮功能障碍，表现为FMD增加和脂联素水平改善（UMIN临床试验注册系统，试验ID为UMIN 000004236）。
The vascular endothelial function is impaired in the very early stage of atherosclerosis in diabetic patients. The goal of this study was to identify the mechanism underlying the improvement in vascular endothelial function by sitagliptin in type 2 diabetes mellitus patients. This study was an open-labeled prospective observational single arm trial. Forty patients were treated with 50 mg of sitagliptin once daily for 12-weeks. The flow-mediated dilation (FMD) and plasma adiponectin were measured at baseline and 12 weeks after initiating treatment. The %FMD was significantly increased after treatment (4.13 ± 1.59 vs 5.12 ± 1.55, P < 0.001), whereas the nitroglycerin-mediated dilation (NMD) did not change. The plasma adiponectin levels significantly increased (13.0 ± 11.3 vs 14.3 ± 12.8, P < 0.001). The changes in the FMD were significantly correlated with those of the plasma adiponectin (r = 0.322, P < 0.05). A multivariate linear regression analysis demonstrated that the improvement in the FMD is associated with the plasma adiponectin (P < 0.05). The treatment of type 2 diabetes mellitus patients with sitagliptin reverses vascular endothelial dysfunction, as evidenced by increase in the FMD, and improvement of the adiponectin levels (UMIN Clinical Trials Registry System as trial ID UMIN000004236).
登录
查看更多内容
影响因子：
3.2
作者：
Lee, Ji-Won;Lee, Hye-Ree;Lee, Duk-Chul
通讯作者：
Lee, Duk-Chul
影响因子：
5.3
作者：
Papathanassiou, Katerina;Naka, Katerina K.;Michalis, Lampros K.
通讯作者：
Michalis, Lampros K.
影响因子：
4.2
作者：
Frederich, Robert;Alexander, John H.;Mahaffey, Kenneth W.
通讯作者：
Mahaffey, Kenneth W.
影响因子：
15.9
作者：
NAUCK, MA;HEIMESAAT, MM;CREUTZFELDT, W
通讯作者：
CREUTZFELDT, W
影响因子：
5.9
作者：
Pepine, Carl J.
通讯作者：
Pepine, Carl J.